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Background: Li-Fraumeni-Syndrome (LFS) is an autosomal-dominant, inherited tumour predisposition syndrome
associated with heterozygous germline mutations in the TP53 gene. Patients with LFS are at a high risk to develop
early-onset breast cancer and multiple malignancies, among which sarcomas are the most common. A high
incidence of childhood tumours and close to 100% penetrance has been described. Knowledge of the genetic
status of the TP53 gene in these patients is critical not only due to the increased risk of malignancies, but also
because of the therapeutic implications, since a higher rate of radiation-induced secondary tumours in these
patients has been observed.
Case report: We report a patient with LFS harbouring heterozygous, pathogenic TP53 germline mutation, who was
affected by four synchronous malignancies at the age of 40: a myxofibrosarcoma of the right upper arm, bilateral
breast cancer and a periadrenal liposarcoma. Radiological treatments and a surveillance program were adjusted
according to recommendations for LFS patients.
Conclusion: Management of tumour treatment of patients with LFS is different to the general population because
of their risk for secondary cancers in the radiation field. Screening procedures should take a possibly elevated risk
for radiation induced cancer into account.
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Li-Fraumeni-Syndrome (LFS; OMIM #151623) is a rare
autosomal-dominant, inherited tumour predisposition
syndrome associated with an increased risk of a variety of
malignancies. Recent statistical analyses stress the rele-
vance of four “core” cancers which account for 77% of all
associated cancers: breast cancer, sarcomas, brain tumours
and adrenocortical carcinoma (ACC) [1]. LFS is character-
ized by high penetrance [2] and early-onset tumours [3,4].
The lifetime risk is higher, and age of onset is earlier in
women compared to men [5,6]. Several criteria, classical
and Li-Fraumeni-like (LFL), have been developed to iden-
tify patients and families with LFS [4,7-11] (Table 1).* Correspondence: karin.kast@uniklinikum-dresden.de
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reproduction in any medium, provided the orLFS is associated with heterozygous germline mutations in
the tumor protein p53 (TP53) tumour suppressor gene.
Mutations in TP53 are detected in ~80% of individuals ful-
filling the classic LFS criteria and ~30% of those fulfilling
the LFL criteria (Table 1) [2,12-14]. In order to increase
the sensitivity of detection, the Chompret criteria were
adjusted in 2009, for age and tumour spectrum parameters
(Table 2). Genetic testing for TP53 is recommended by the
National Comprehensive Cancer Network (NCCN, http://
www.nccn.org) in accordance with the Chompret criteria,
or in any breast cancer patient< 30 years of age testing
negative test for BRCA1 and BRCA2 mutations.
TP53 encodes a transcription factor implicated in cell-
cycle control, apoptosis and genomic stability [15,16].
Impaired TP53 function may not only influence tumour
response to radiotherapy and chemotherapy, but also
confers an elevated risk for therapy-induced secondary. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Description of different criteria for Li-Fraumeni Syndrome (LFS) or Li-Fraumeni-like (LFL) Syndrome
Criteria Description
LFS classic Li-Fraumeni [4] Proband diagnosed with sarcoma before 45 years, AND
• a first-degree relative with cancer before 45 years, AND
• another first- or second-degree relative with any cancer diagnosed
under the age of 45 years or with sarcoma at any age
LFL Chompret original [9] 1. Proband with a ”core cancer” before 36 years, AND at least one
first- or second-degree relative with
• cancer (other than breast cancer if the proband has breast cancer)
under the age of 46 years OR
• multiple primaries at any age
2. Proband with multiple primary tumours, two of which are
“core cancers”, with the initial cancer occurring before 36 years,
regardless of the family history
3. Proband with adrenocortical carcinoma at any age of onset,
regardless of the family history
LFL Chompret 2009 update [10] 1. Proband with a tumour belonging to the LFS tumour spectrum
before 46 years, AND
• at least one first- or second-degree relative with cancer
(other than breast cancer if the proband has breast cancer)
under the age of 56 years OR
• a relative with multiple primaries at any age
2. Proband with multiple primary tumours (except multiple breast tumours),
two of which belong to the LFS spectrum, with the initial cancer occurring
before the age of 46 years, regardless of the family history
3. Proband with adrenocortical carcinoma or plexus tumour at any age of onset,
regardless of the family history
LFL Birch [6] Proband with any childhood cancer or sarcoma, brain tumour,
or adrenocortical carcinoma diagnosed under 45 years of age, AND
• a first- or second-degree relative with a typical LFS-related cancer
(“core cancers” and leukaemia) diagnosed at any age, AND
• a first- or second-degree relative in the same genetic lineage with any
cancer diagnosed under the age of 60 years
LFL Eeles [7] Two different tumours that are “core cancers” or leukaemia in first- or
second-degree relatives at any age
Li-Fraumeni Syndrome NCCN-Guidelines since 2010 Classic LFS-Criteria OR LFL according to Chompret 2001/2009 OR
Early onset breast cancer: Individual with breast cancer <30 years of age
with a negative BRCA1/BRCA2 test, especially if there is a family
history of sarcoma, brain tumour, adrenocortical carcinoma or chorid plexus carcinoma
Tumour spectrum: Five “core cancers”: sarcoma, brain tumour, breast cancer or adrenocortical carcinoma plus e.g. leukaemia, lung bronchoalveolar cancer
Abbreviations: NCCN=National Comprehensive Cancer Network.
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dose radiation exposure by diagnostic methods [4,17].
We hereby present a case with LFS and relatively late
tumour onset, in which a de novo mutation in TP53 was
identified. Response to adjuvant therapy, treatment
modification as well as further screening modalities in
patients with LFS are discussed.
Case presentation
Myxofibrosarcoma of the right upper arm
In August 2006, a 40-year old female patient was exam-
ined for swelling in the lateral side of the right upper arm.Upon resection, the patient was diagnosed with myxofi-
brosarcoma. A second resection was performed to achieve
tumour-free margins and plastic surgery was performed
two times on the damaged area for cosmetic purposes.
Screening for metastatic disease by computer tomog-
raphy (CT) showed no pulmonary, bone or hepatic metas-
tases, however a lesion (36 × 23 mm diameter), classified
as a benign tumour by CT criteria, was detected adjacent
to the left adrenal gland. A control CT scan in December
2006 revealed that this lesion had increased in size. Biopsy
of the periadrenal tumour indicated a possible mesenchy-
mal tumour, however malignancy was not confirmed.
Table 2 Chronologic synopsis of case report
Year / Month Sarcoma/Carcinoma Stage Therapy Follow up
2006/08 (40 y) Myxofibro-sarcoma
right upper arm
pT1a, pNx, pMx, G2, R0 Incomplete resection, R1, 2006/08 palpation,
Re-Resection, R1, 2006/09 12-mo MRI
Re-Re-Resection with musculo-cutaneous
flap 2006/11
2006/12 (40 y) Breast cancer
right side
ypT2 ypN1a (2/13) yM0 L0
V0 R0 yG3, ER IRS 2,
PR IRS 9, Her2neu pos.,
IRS 3, invasive ductal carcinoma
Neo-adj. CT with 4x FEC, 2007/01-04, prophylactic
Lumpectomy and axillary dissection 2007/05, mastectomy offered
Adj. CT, 4x P 2007/06-08, 3-mo palpation,
HerceptinW 2007/09-2008/06 6-mo ultrasound,
GnRH Analoga+ TAM 07/09-ongoing 12-mo MRI
2006/12 (40 y) Breast cancer
left side
ypT1c ypN1mic (1/17) yM0
L0 V0 R0 yG3, ER IRS 8,
PR IRS 12, Her2neu pos. IRS 3,
invasive ductal carcinoma
see above see above
2007/05 (40 y) Liposarcoma
periadrenal left
pT2b pN0 (0/2 LK) pMx L0 V0 G3,
Rx, pleomorph sarcoma
Lumbal left adrenalectomy 2007/05, MRI
Radiation therapy (66 Gy) 2007/08-10
2008/05 (41 y) Recurrence
Recurrence
ypT2 ypN0 (0/14) ypMx G1
R1(vessel)
CT with 2xIfos 2008/06, followed by
Trabectedin, Mini-ICE and Hyperthermia
2009/01-05
Compartment resection with hemicolectomy,
splenectomy, partial diaphragm resection and
resection of 11th costa 2009/06
2010/06 Recurrence CT with Trabectedin since 2010/06
Abbreviations: Neo-adj. = neo-adjuvant, Adj. = adjuvant, CT = Chemotherapy, FEC = 5-FU 500 mg/², Epirubicine 100 mg/m², Cyclophosphamide 500 mg/m², q21d,
P= Paclitaxel 175 mg/m², q21d, TAM= TamoxifenW, Ifos = Ifosfamide, mo=monthly, Mini-ICE = Ifosfamid, Carboplatin, Etoposide.
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In addition, suspect bilateral mammary lesions were also
diagnosed. Histological examination of biopsies taken
from both breast tumours, revealed invasive ductal car-
cinomas on both sides.
Because of an unfavourable breast-tumour-relation, neo-
adjuvant chemotherapy was applied. After four cycles of an
anthracycline-containing regimen, restaging revealed no
significant change in the breast tumours, however progres-
sion of the periadrenal mass which extended in diameter
to 67× 49 mm, was identified by CT scan. Firstly, a bilateral
breast-conserving tumour extirpation in combination with
bilateral axillary lymphonodectomy was performed. Both
carcinomas were positive for oestrogen receptor (ER) and
progesterone receptor (PR) expression in the majority of
tumour cells, and also overexpressed the human epidermal
growth factor receptor (HER2/neu) (Table 2). There were
no relevant histological signs of regression 3 months fol-
lowing neo-adjuvant chemotherapy.
Periadrenal liposarcoma
The periadrenal tumour was subsequently resected. Histo-
logical diagnosis revealed a poorly differentiated, pleo-
morphic, periadrenal liposarcoma. The lipogenic nature of
tumour was confirmed by immunohistochemical detec-
tion of the S100 protein in the tumour cells. Adjuvant
chemotherapy with taxanes was recommended followingconsultation with an interdisciplinary tumour board,
because of the nodal positive breast cancer. Post-operative
radiation of the periadrenal region due to RX resection of
the periadrenal liposarcoma was also scheduled upon com-
pletion of the chemotherapy. Treatment with Trastuzumab
and endocrine treatment was included according to the
receptor status of the bilateral breast cancers. Moreover,
radiation therapy after bilateral breast conserving therapy
and radiation of the right upper arm was planned.
Genetic counselling and molecular analysis
Family history revealed a paternal uncle who died at
22 years from a malignancy in the splenic region. No
further information regarding this tumour was available.
Additionally, the paternal grandfather was diagnosed
with leukaemia at 70 years. The maternal grandmother
died from colorectal cancer diagnosed at 51 years. Cri-
teria for Li-Fraumeni-like syndrome according to Eeles
and the updated Chompret criteria were met (Table 1)
[8]. Genetic analysis of TP53 was performed by sequen-
cing genomic DNA isolated from peripheral blood leu-
kocytes of our patient. A pathogenic, heterozygous
germline mutation (p.Arg282Trp) was identified. Neither
parent was shown to be a carrier of this mutation. Pater-
nity was confirmed by using 15 high polymorphic Short-
Tandem-Repeats. Taken together, these data indicate
that the TP53 mutation in the patient occurred de novo,
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cannot be excluded. We examined tissue from a differ-
ent germ layer to identify possible somatic mosaicism in
the patient. Analysis of DNA from the oral mucosa
revealed the same heterozygous TP53 mutation identi-
fied in the leucocytes. Thus, although we cannot rule
out somatic mosaicism, this was very unlikely. Predictive
testing was performed in the 44 year-old sibling and in
both daughters (aged 21 and 18 years) of the patient. All
three female subjects were not carriers of the mutation.
Analyses of BRCA1 and BRCA2 genes in the index
patient did not reveal any pathological findings.
Therapy modification for supposed radiation sensitivity
After confirmation of LFS by molecular analysis, the deci-
sion of an interdisciplinary consulting panel was to restrict
the planned radiotherapy to the location with the highest
priority. This decision was based on the suspected radio-
sensitivity of individuals harbouring a deleterious mutation
in TP53. Thus, radiation was scheduled for the periadrenal
region with postoperative RX, however the initially
intended radiotherapy of both breasts, as well as of the
right upper arm was cancelled.
Surveillance strategies
The patient was offered secondary, bilateral prophylactic
mastectomy, to reduce the risk of recurrent breast can-
cer. Due to the risk of new primary tumours at other
sites, the patient refused this option and opted for a
close, post-treatment observation regimen. The surveil-
lance program was adjusted to her elevated risk for
other primary malignancies and secondary malignancies
after radiotherapy. Biannual ultrasound examination of
the breast, annual magnetic resonance imaging (MRI) of
the breast, and mammography at larger intervals were
recommended. Abdominal ultrasound and MRI were
predominantly used to monitor the sites of sarcomas.
Recurrent disease of the periadrenal liposarcoma
In June 2008, multiple nodular lesions were detected
close to the left kidney by control MRI, inside and adja-
cent to the former irradiation region. The optimal
response to several lines of treatment with chemother-
apy was stable disease. A radical resection of the tumour
mass was performed in June 2009. Histological analysis
confirmed a recurrent, but well-differentiated liposar-
coma. The short interval to radiation therapy of the left
periadrenal region indicated resistance of the disease to
radiation therapy.
In June 2010, MRI of the abdomen revealed local recur-
rence. As of February 2012, the patient has been under
long-term treatment with trabectedine at a Karnofsky
Index of 80%. No distant metastasis, new primaries or
recurrences at other sites have since been identified.Conclusions
In this report, we describe a 40-year old, female patient
with four concurrent primary malignant tumours. The
simultaneous occurrence of four malignancies is uncom-
mon, and metastases should be excluded. Indeed, all four
tumours exhibited morphological features consistent with
their histogenesis. Both breast cancers were hormone
receptor positive and included intraductal components as
precursor lesions for invasive carcinomas. A recent study
by Melhem-Bertrandt et al., described an ER positive/
HER2 positive phenotype for breast cancer in TP53 germ-
line mutation carriers [18]. This study also observed that
in cases of bilaterality, both tumours were HER2 positive.
In our patient, examination of the entire myxofibrosar-
coma did not reveal any lipogenic morphology, and simi-
larly, the liposarcoma did not exhibit a myxoid or non-
lipogenic component. Furthermore, the liposarcoma
expressed the S100 protein, which is an established mar-
ker for lipogenic differentiation. The typical combination
of sarcomas and early-onset breast cancer was indicative
of LFS and subsequent genetic analysis confirmed a germ-
line mutation in the TP53 gene. While the patient met
some of the wider Li-Fraumeni-like-criteria, she did not
meet the classical LFS criteria [4]. The age at onset for the
first malignancy was relatively high, as the estimated pene-
trance at 40 years of age ranges between 77%–100% [5].
The average age for diagnosis of first cancers in TP53 mu-
tation carriers is estimated to be 21.9 years, and this is
earlier in females than in males [1,5]. Predictive testing of
minors is recommended since a high prevalence of
adrenal gland, soft tissue and brain tumours has been
observed in children
Testing of both parents indicated a de novo TP53 muta-
tion in the patient. De novo TP53 mutations have been
described in up to 23.5% (4 of 17) of carriers [9,19].
Recently, de novo TP53 mutations were confirmed in 7%
and suspected in up to 20% of a larger cohort with 75
germline mutation carriers [20].
Treatment response to adjuvant therapy and prognosis
Impaired response to chemotherapy and radiation is
described in most studies [21-24]. In breast cancer, TP53
status was identified as independent negative prognostic
marker [25], however the results remain controversial.
The response to treatment ranges from a high rate of
pathologic complete remission of breast cancer after
neoadjuvant chemotherapy with anthracyclines, to pri-
mary tumour resistance and progression as observed in
the case of our patient [26-31]. Introduction of wild-type
TP53 by gene therapy increased the response to chemo-
therapy or radiation therapy in preclinical and some
early clinical trials [27,32-34], however the results were
not consistent and to date, gene therapy is not within
reach for patients with LFS.
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The risk of developing secondary, radiation-induced
malignancies was described as elevated in LFS patients,
since the first reports of LFS by Li and Fraumeni [3].
Several case-reports point to the appearance of metachro-
nous cancers in radiation-treated areas in cancer patients
with TP53 mutations [35-39].
Data regarding secondary cancers after radiation ther-
apy in young LFS patients is limited, because of the un-
favourable prognosis of most core cancers in LFS and
the expected time delay in radiation-induced cancers
[19]. Interestingly, five long-term in-field relapses or sec-
ond primary cancers were recently reported in six
patients with unilateral breast cancer, following radiation
treatment [39]. In a study of 27 LFS patients, nine were
treated with radiotherapy. Of these, six patients suffered
from one or two successive solid tumours in the radi-
ation field within a period of 3–22 years (median 7 years)
after treatment for the first malignancy. One additional
cancer was identified in the radiation field of a patient
following treatment for a third cancer, after a delay of
7 years [17]. In a separate study, three radiotherapy-
treated patients in a series of nine children with adreno-
cortical tumours and known TP53 mutations, survived
more than two years, however these children developed
five secondary malignancies in the radiation fields [19].
Preclinical studies support the hypothesis that cells lack-
ing wild-type TP53 function have an increased likelihood
of genetic instability due to high rates of inappropriate
recombination after radiation-induced DNA damage
(reviewed in Cuddihy et al., [40]). In Trp53-heterozygous
or Trp53-null mice, treatment with low-dose irradiation
led to shorter latency of tumour development and a
higher incidence of malformations [41-43]. Human
TP53-deficient cells have been shown to accumulate
DNA damage and are susceptible to malignant trans-
formation, whereas TP53-competent cells showed cell-
cycle arrest facilitating DNA repair, or apoptosis [44].
These data support the observation that LFS patients are
more likely to develop radiotherapy-induced secondary
cancers. Finally, it appears that in addition to TP53 var-
iations, the presence of additional genetic alterations are
required to predict the individual risk for radiation-
induced secondary cancers [45,46].
Need for therapy modification in LFS patients
Due to the potentially higher cancer induction rate after
radiotherapy, it is important to consider the existence of a
germline TP53-mutation, especially if there is a choice
between surgery and radiotherapy [47,48]. After bilateral,
breast-conserving resection, the initial plan to apply adju-
vant radiation therapy was cancelled due to the detection
of a germline TP53 mutation. Greater effort should be
taken in the early detection and complete resection ofTP53-associated malignancies, since DNA-damaging,
standard adjuvant therapies not only have a questionable
effect, but also carry the risk for secondary tumours.
Surveillance
Most of the core cancers of LFS are associated with a poor
prognosis. Interestingly, the first prospective data on the
successful application of a surveillance programme in
TP53 mutation carriers was recently published. The key
imaging procedure was an annual rapid total body MRI
starting in childhood. Compared to the control group, this
study demonstrated a potential survival benefit using a
comprehensive screening program [49].
Genetic counselling and predictive testing should be
offered to patients fulfilling the classic LFS or Li-
Fraumeni-like criteria, as well as to their relatives, in order
to recommend an intensified cancer screening if LFS is
confirmed. While the NCCN guidelines recommend the
testing of singular cases suggestive for LFS, even in the
absence of family history, others negate the necessity for
testing because of low mutation rates (0–7%) and high
psychological burden. Numerous publications have
explored the testing of early onset breast cancer cases for
TP53 germline mutations and found that these represent
rare cases [1,11,50-57]. For example, no pathologic muta-
tions were found in 95 patients with breast cancer
(< 30 years old), despite the fact that several patients dis-
played a positive family history for breast and ovarian can-
cer [50]. As the costs of testing decrease in the future and
effective prevention strategies may be confirmed, testing
patients with early onset breast cancer without a family
history of cancer will become even more feasible.
In comparison to other tumour syndromes, such as her-
editary breast and ovarian cancer, prophylactic operations
do not offer a good prognosis for carriers of a TP53 germ-
line mutation, and each case should be considered indi-
vidually. Firstly, the life-time breast cancer risk is
estimated to be ~22%. This is significantly lower than for
carriers of a pathogenic mutation in BRCA1 or BRCA2,
who display a life-time risk for breast cancer of ~60–80%.
Secondly, in LFS, malignancies emerge in different ana-
tomical sites, whereas BRCA-associated tumours mainly
affect the breast and ovaries.
Since some LFS patients seem to carry an elevated risk
for radiation-induced malignancies, exposure should be
as low as possible, although a general contraindication
for any type of radiological diagnostic or treatment can-
not be stated. Surveillance strategies should be chosen
with regard to the least possible radiation exposure.
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